Status: Recruiting
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination.
Participants needed: 75
Trial details
Phase: Phase 1Age: 65-100Biological sex: AllType: InterventionalSponsor: The Methodist Hospital Research InstituteUpdated: Jul 31, 2025Locations: 1
Eligibility criteria
Age 65 or greater. [+3]
Hypoxemia for any reason, defined as either oxygen saturation (SpO2) ≤ 93% on ro... [+27]